Experiencia clínica con efalizumab en el Hospital de Cruces

Martínez de Lagrán, Z; González Hermosa, MR; Díaz-Pérez, JL

doi:10.1016/S0210-5705(09)71003-9

Actas Dermo-Sifiliográficas

ISSN: 0001-7310

The Official publication of the Spanish Academy of Dermatology and Venereology (AEDV). Actas Dermo-Sifiliográficas, founded in 1909, is the oldest monthly medical journals published in Spain. In the year 2006 has been indexed in the Medlinedatabase, and has become a vehicle for expressing the most current Spanish medicine and modern. All articles are subjected to a rigorous process of revision in pairs, and careful editing for literary and scientific style. Together with the classic Original and Clinical Case Study sections, we also include Reviews, Case Diagnoses, and Book Reviews. Dermo-Sifiliográficas is an essential publication for anyone who needs to be current on all aspects of Spanish and world dermatology.

Con su JCI 2023, Actas Dermo-Sifiliográficas es Q1 y se posiciona la revista nº 15 de 94 en Dermatología

With JCI 2023, Actas Dermo-Sifiliográficas is Q1 and is ranked number 15 of 94 in Dermatology

Indexed in:

Web of Science, Emerging Sources Citation Index (WoS, Clarivate), PubMed/Medlinee, IME, Embase/Excerpta Medica, Embase, Toxline, Cab Abstracts, Cab Health, Cancerlit NIm, Serline: Biomed, Bibliomed, Pascal, Scopus , IBECS

Efalizumab (Raptiva®) es uno de los agentes biológicos aprobados recientemente para el tratamiento de pacientes con psoriasis de intensidad moderada-grave que no hayan respondido a tratamientos convencionales. Es un anticuerpo monoclonal humanizado que por su efecto anti-CD11 es capaz de bloquear la migración endotelial y la activación de los linfocitos T a nivel cutáneo, procesos fundamentales en la etiopatogenia de la psoriasis. Presentamos la experiencia que a lo largo de los dos últimos años hemos tenido en nuestro hospital con los 23 pacientes que han iniciado tratamiento con efalizumab.

Palabras clave:

efalizumab, Raptiva®, psoriasis

Efalizumab (Raptiva®) is one of the biological agents approved recently for the treatment of patients with moderate-severe psoriasis who have not responded to conventional treatments. It is a humanized IgG1 monoclonal antibody which, due to its anti-D11 effect, is capable of blocking the endothelial migration and T cell activation on the skin, fundamental processes in the etiopathogeny of psoriasis. We present the experience we have had in our hospital over the last two years with 23 patients who have initiated treatment with efalizumab.

Keywords:

efalizumab, Raptiva®, psoriasis

Full text is only aviable in PDF